Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Cost of Revenue (2016 - 2025)

Corcept Therapeutics' Cost of Revenue history spans 10 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 13.9% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $13.0 million, up 19.25%, while the annual FY2025 figure was $13.0 million, 19.25% up from the prior year.
  • Cost of Revenue for Q4 2025 was $2.5 million at Corcept Therapeutics, down from $4.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $4.6 million in Q3 2025 and bottomed at $1.2 million in Q1 2022.
  • The 5-year median for Cost of Revenue is $1.6 million (2023), against an average of $2.1 million.
  • The largest annual shift saw Cost of Revenue tumbled 32.48% in 2021 before it surged 82.9% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $1.4 million in 2021, then rose by 9.31% to $1.5 million in 2022, then rose by 26.76% to $1.9 million in 2023, then skyrocketed by 57.57% to $3.0 million in 2024, then dropped by 13.9% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Cost of Revenue are $2.5 million (Q4 2025), $4.6 million (Q3 2025), and $3.4 million (Q2 2025).